North Central London NHS Integrating Pharmacy & Medicines Optimisation Team, London, UK.
Clinical Support Services Division, University College London Hospitals NHS Foundation Trust, London, UK.
Br J Clin Pharmacol. 2023 Sep;89(9):2649-2657. doi: 10.1111/bcp.15820. Epub 2023 Jul 20.
Pharmacogenomic testing has the potential to target medicines more effectively towards those who will benefit and avoid use in individuals at risk of harm. Health economies are actively considering how pharmacogenomic tests can be integrated into health care systems to improve use of medicines. However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost-effectiveness, and operational requirements. We sought to develop a framework that could aid the implementation of pharmacogenomic testing. We take the view from the National Health Service (NHS) in England.
We used a literature review using EMBASE and Medline databases to identify prospective studies of pharmacogenomic testing, focusing on clinical outcomes and implementation of pharmacogenomics. Using this search, we identified key themes relating to the implementation of pharmacogenomic tests. We used a clinical advisory group with expertise in pharmacology, pharmacogenomics, formulary evaluation, and policy implementation to review data from our literature review and the interpretation of these data. With the clinical advisory group, we prioritized themes and developed a framework to evaluate proposals to implement pharmacogenomics tests.
Themes that emerged from review of the literature and subsequent discussion were distilled into a 10-point checklist that is proposed as a tool to aid evidence-based implementation of pharmacogenomic testing into routine clinical care within the NHS.
Our 10-point checklist outlines a standardized approach that could be used to evaluate proposals to implement pharmacogenomic tests. We propose a national approach, taking the view of the NHS in England. Using this approach could centralize commissioning of appropriate pharmacogenomic tests, reduce inequity and duplication using regional approaches, and provide a robust and evidence-based framework for adoption. Such an approach could also be applied to other health systems.
药物基因组学检测有可能将药物更有效地针对那些将受益的人群,并避免在有潜在风险的人群中使用。卫生经济体正在积极考虑如何将药物基因组学检测纳入医疗保健系统,以改善药物的使用。然而,有效实施的一个障碍是评估证据,包括临床实用性、成本效益和操作要求。我们试图开发一个框架,以帮助实施药物基因组学检测。我们从英国国民健康服务(NHS)的角度出发。
我们使用 EMBASE 和 Medline 数据库进行文献综述,以确定药物基因组学检测的前瞻性研究,重点关注临床结果和药物基因组学的实施。利用这一搜索,我们确定了与药物基因组学检测实施相关的关键主题。我们利用具有药理学、药物基因组学、处方评估和政策实施专业知识的临床顾问小组,审查我们文献综述中的数据以及对这些数据的解释。在临床顾问小组的帮助下,我们对主题进行了优先级排序,并开发了一个框架,以评估实施药物基因组学检测的建议。
从文献综述和随后的讨论中提炼出的主题被提炼成一个 10 点清单,该清单被提议作为一个工具,以帮助在 NHS 中基于证据实施药物基因组学检测。
我们的 10 点清单概述了一种标准化方法,可用于评估实施药物基因组学检测的建议。我们提出了一种以英国国民健康服务(NHS)为视角的全国性方法。使用这种方法可以集中委托适当的药物基因组学检测,减少区域方法的不平等和重复,并为采用提供一个稳健的基于证据的框架。这种方法也可以应用于其他卫生系统。